1. Back to Outputs Catalog

Disruption of Mitochondrial Complex I Induces Progressive Parkinsonism

February 22, 2022

Training and Networking Working Group

Disruption of mitochondrial complex I induces progressive parkinsonism

View Article

Mitochondrial dysfunction is recognized as being an important mechanism through which Parkinson’s disease (PD) can arise. In particular, decrease of mitochondrial complex 1 (MCI) activity in dopaminergic neurons of the substantia nigra (SN) has been observed in PD; however, its role in the pathogenesis of PD remains unclear.1, 2 Mitochondrial protection or rescue therapies are potential approaches through which disease modification of PD may be achieved in the future.

Training and Networking Working Group

The Training and Networking working group promotes training and networking throughout the GP2 project.
Learn more about Training and Networking Working Group

Meet the authors

Research Professor / Principal Investigator , Senior Researcher

Mario Cornejo-Olivas, MD

Universidad Científica del Sur, Instituto Nacional de Ciencias Neurológicas | Lima, Peru

PhD Candidate

Lesley Wu, MSc

University College London | London, UK

Principal Investigator

Alastair Noyce, MD, PhD

Queen Mary University of London | London, UK

More outputs and publications

Team Science Approaches to Unravel Monogenic Parkinson's Disease on a Global Scale
In this article, we describe combining both efforts in a merger project resulting in a global monogenic PD cohort with the buildup of a sustainable infrastructure to identify the multi-ancestry spectrum of monogenic PD and enable studies of factors modifying penetrance and expressivity of monogenic PD.
Read More
Clinical and functional evidence for the pathogenicity of the LRRK2 p.Arg1067Gln variant
LRRK2-related Parkinson’s disease (LRRK2-PD) is the most frequent form of monogenic PD worldwide, with important therapeutic opportunities, exemplified by the advancement in LRRK2 kinase inhibition studies/trials. However, many LRRK2 variants, especially those found in underrepresented populations, remain classified as variants of uncertain significance (VUS). Leveraging on Malaysian, Singaporean, and mainland Chinese PD datasets (n=4,901), we describe 12 Chinese-ancestry patients harbouring the LRRK2 p.Arg1067Gln variant, more than doubling the number of previously reported cases (total n=23, 87% East Asian, mean age of onset:53.9years). We determine that this variant is enriched in East Asian PD patients compared to population controls (OR=8.0, 95%CI:3.0-20.9), and provide supportive data for its co-segregation with PD, albeit with incomplete penetrance. Utilizing established experimental workflows, this variant showed increased LRRK2 kinase activity, by ~2-fold compared to wildtype and higher than the European p.Gly2019Ser variant. Taken together, p.Arg1067Gln should be reclassified from a VUS to pathogenic for causing LRRK2-PD.
Read More
Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2)
The Monogenic Network of the Global Parkinson’s Genetics Program (GP2) aims to create an efficient infrastructure to accelerate the identification of novel genetic causes of Parkinson’s disease (PD) and to improve our understanding of already identified genetic causes, such as reduced penetrance and variable clinical expressivity of known disease-causing variants. We aim to perform short- and long-read whole-genome sequencing for up to 10,000 patients with parkinsonism. Important features of this project are global involvement and focusing on historically underrepresented populations.
Read More